Abstract：
:Health technology assessment (HTA) has become an integral part of decision-making on the coverage of new health technologies in most health systems in the developed world. In recent years, pressure to involve patients and members of the public in HTA has grown. In this article, we summarize findings from peer-reviewed and 'gray' literature, and discussions with key informants to determine potential roles for patients and the public in HTA and coverage decision-making. We also summarize existing roles for both groups in jurisdictions. Although there appears to be a general view that involvement of patients and the public is highly desirable, research offering insights into the effectiveness of different approaches to accomplish this is scarce. Nonetheless, many of the HTA agencies in developed countries have established some mechanism for seeking input from patients or the public in their processes.
journal_name
Expert Rev Pharmacoecon Outcomes Resjournal_title
Expert review of pharmacoeconomics & outcomes researchauthors
Menon D,Stafinski Tdoi
10.1586/erp.10.82subject
Has Abstractpub_date
2011-02-01 00:00:00pages
75-89issue
1eissn
1473-7167issn
1744-8379journal_volume
11pub_type
杂志文章,评审abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2014.940902
更新日期：2014-10-01 00:00:00
abstract：:The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.6.2.145
更新日期：2006-04-01 00:00:00
abstract：:Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.4.3.277
更新日期：2004-06-01 00:00:00
abstract：:Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.7.2.137
更新日期：2007-04-01 00:00:00
abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type：
doi：10.1586/erp.11.91
更新日期：2012-02-01 00:00:00
abstract：:Rheumatoid arthritis is a chronic inflammatory musculoskeletal disease with a prevalence rate of 1-3% in Western countries. In addition to limited physical function, rheumatoid arthritis patients also suffer from psychologic comorbidities. Depression in rheumatoid arthritis patients has been linked to disease outcomes...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.5.5.645
更新日期：2005-10-01 00:00:00
abstract：INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1080/14737167.2019.1554437
更新日期：2019-04-01 00:00:00
abstract：:Treatment switching has become an important issue in the development and approval of new drugs, particularly in oncology. Randomized controlled trials (RCTs) represent the gold standard for evaluating the effectiveness of interventions, but often patients randomized to the control group are permitted to switch onto th...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 社论
doi：10.1586/14737167.2015.1037835
更新日期：2015-01-01 00:00:00
abstract：:The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type：
doi：10.1586/erp.11.84
更新日期：2011-12-01 00:00:00
abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.3.2.125
更新日期：2003-04-01 00:00:00
abstract：OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2015.1065734
更新日期：2015-01-01 00:00:00
abstract：:Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.8.5.453
更新日期：2008-10-01 00:00:00
abstract：:The Dutch basic health insurance is based on the principles of regulated competition. This implies that insurers and providers compete on price and quality while the regulator sets certain rules to achieve public objectives such as solidarity. Two regulatory aspects of this scheme are that insurers are not allowed to ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1586/14737167.2013.841546
更新日期：2013-12-01 00:00:00
abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1080/14737167.2017.1375407
更新日期：2018-04-01 00:00:00
abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1586/erp.11.27
更新日期：2011-06-01 00:00:00
abstract：:Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 评论,杂志文章
doi：10.1586/14737167.3.3.223
更新日期：2003-06-01 00:00:00
abstract：BACKGROUND:This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1080/14737167.2019.1632194
更新日期：2020-06-01 00:00:00
abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2014.940903
更新日期：2014-10-01 00:00:00
abstract：:This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.5.3.297
更新日期：2005-06-01 00:00:00
abstract：:Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2.4.337
更新日期：2002-08-01 00:00:00
abstract：INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2016.1141679
更新日期：2017-02-01 00:00:00
abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1586/erp.13.26
更新日期：2013-06-01 00:00:00
abstract：:The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1586/erp.11.57
更新日期：2011-10-01 00:00:00
abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,多中心研究
doi：10.1080/14737167.2018.1386561
更新日期：2018-04-01 00:00:00
abstract：OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1080/14737167.2018.1384696
更新日期：2018-04-01 00:00:00
abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,评审
doi：10.1586/erp.10.66
更新日期：2010-10-01 00:00:00
abstract：:A comprehensive literature search identified seven instruments, of which three had psychometric data available. These were the 'Sawicki instrument', the Duke Anticoagulation Satisfaction Scale (DASS) and Deep Vein Thrombosis Quality of Life (DVTQoL). Sawicki assessed five domains with acceptable internal reliability. ...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.8.3.291
更新日期：2008-06-01 00:00:00
abstract：:The aim of this systematic review was to collect all current data on indirect costs related to inflammatory bowel disease as well as assessing homogeneity and comparability, and conducting a meta-analysis. Costs were collected using databases from Medline, Embase and Centre for Reviews and Dissemination databases, the...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章,meta分析,评审
doi：10.1586/14737167.2015.1011130
更新日期：2015-04-01 00:00:00
abstract：BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1080/14737167.2016.1223543
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...
journal_title：Expert review of pharmacoeconomics & outcomes research
pub_type： 杂志文章
doi：10.1586/14737167.2015.1081061
更新日期：2016-01-01 00:00:00
